The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.

Given the prevalence of managed care, it’s incumbent upon the industry to ensure that there is a robust supplier pool.

While evidence-based decisions are essential, they must be paired with effective public messaging that builds trust and ...

Oklahoma and South Carolina are among nine states that use some form of provider-based reference pricing to contain spending ...

We examine key lessons on medical-dental integration from the Program of All-Inclusive Care for the Elderly (PACE), ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Paige Nong of the University of Minnesota about her recent paper that evaluates and explores the current use of artificial intelligence and ...

This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from The American Society of Hematology. The articles in the ...

President Trump reinstated an expanded version of the so-called “Mexico City policy,” which prevents organizations that receive federal global health funding from providing access to abortion-related ...

Health Affairs presents a new collection of commentary articles in 2025 from the National Academy of Medicine’s (NAM’s) Vital Directions for Health and Health Care project, offering actionable ...